(lp0
S"Blame This for Orexigen Therapeutics, Inc.'s Mind-Numbingly Bad 2015 Motley Fool - Jan 8, 2016 Shares of Orexigen Therapeutics , a biotechnology company focused on the development of therapies to induce weight loss, collapsed 72% in 2015, based on data from S&amp;P Capital IQ."
p1
aS'Orexigen Therapeutics Announces Commercialization and Distributorship ... PR Newswire  - Aug 1, 2016 SAN DIEGO, Aug. 1, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc.  today announced that wholly owned subsidiary Orexigen Therapeutics Ireland Ltd.'
p2
aS'Orexigen Therapeutics, Inc.  Looks Good For Further Gains Insider Financial - Jan 5, 2017 Orexigen Therapeutics, Inc.  is up 130% on its end of December close, with the company announcing that it is set to put out a fresh advertising for its lead  product.Orexigen Therapeutics  Releases Results Of IGNITE Study Through Obesity ... - StreetInsider.com'
p3
aS'Orexigen Therapeutics Launches &quot;Brains Behind Weight Loss,&quot; a Dynamic Patient ... PR Newswire  - Jan 4, 2017 SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc.  unveiled &quot;Brains Behind Weight Loss,&quot; a new, national direct-to-consumer advertising campaign demonstrating to patients how the brain plays an important role in weight&nbsp;...'
p4
aS'Orexigen Announces Presentation of Data for OREX-1019, a Preclinical Candidate ... PR Newswire  - Nov 16, 2016 SAN DIEGO, Nov. 16, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc.  today announced the presentation of preclinical data for OREX-1019  at Neuroscience 2016, the 46th annual meeting of the Society of Neuroscience, being&nbsp;...'
p5
aS"Orexigen Therapeutics Announces Stockholder Approval of All Proposals at 2016 ... PR Newswire  - Jul 8, 2016 The Board of Directors and stockholders approved a 1-for-10 reverse stock split of all of the outstanding shares of Orexigen's common stock. The Company expects that shares of Orexigen will begin trading on a post-split basis on July 12, 2016. At the ..."
p6
aS'Orexigen Therapeutics Announces Commercialization and Distributorship ... PR Newswire  - Mar 15, 2016 SAN DIEGO, March 15, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc.  today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba  in Central and&nbsp;...'
p7
aS'The Next 6 Months Are Critical For Orexigen Seeking Alpha - Feb 29, 2016 Slower sales netted Orexigen just $2.6 million in royalty revenue for the quarter, and growth in the overall sector is actually slower than the double digits that the company guided to. Adding insult to injury, RBC Capital came out with a downgrade on ...'
p8
aS'Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason ... PR Newswire  - Jun 8, 2016 SAN DIEGO, June 8, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc.  today announced the promotions of Thomas Cannell, D.V.Orexigen Therapeutics  Stock: Nearly Doubles On Patent News - aomarkets  Orexigen  Names Tom Cannell as COO and Jason Keyes as CFO - StreetInsider.com'
p9
aS"OREXIGEN THERAPEUTICS, INC.  Files An 8-K Regulation FD Disclosure Market Exclusive - Mar 8, 2017 Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a&nbsp;...Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter ... - Yahoo Finance"
p10
a.